Lutz Hegemann, the head of global health at Swiss pharmaceutical manufacturer Novartis, said the company will continue to ...

Switzerland-based global healthcare company Novartis (NVS) is gaining momentum this year, thanks to solid pipeline execution, ...

(Reuters) - Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. Under the ...

Molecular Partners' shares jumped as much as a third on Wednesday after Swiss drugs giant Novartis inked a deal to license two of the Zurich-based biotech company's antiviral drugs that it hopes to ...

Discover the top biotech deals of September 2025, as four billion-dollar acquisitions took place and several licensing deals ...

The findings position Fabhalta to secure a standard approval in IgA nephropathy — a crowded area of drug research — at a time ...

The 7th Annual AI in Drug Discovery Conference, hosted by SAE Media Group, takes place 9-10 March 2026 at Hilton London ...

Cardiovascular disease can be managed with drugs that take various approaches, but few of them work by reducing inflammation. Novartis is getting an anti-inflammatory drug candidate through its $1.4 ...

(Reuters) -The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the Swiss drugmaker said on Tuesday. The twice-daily ...